CliffBio
small molecule

DAPTOMYCIN

DAPTOMYCIN

Loss of exclusivityJanuary 2043latest FDA-listed patent expiry
CompanyHikma →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAPTOMYCIN
Active ingredientDAPTOMYCIN
Strength350MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJanuary 2023
Marketing statusRX

Listed patents

PatentExpiresType
12629337January 2043product
12053502August 2038use U-3981
11759497August 2038product

More from Hikma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DAPTOMYCIN patent cliff — loss of exclusivity January 2043 | CliffBio